CYB5R3 in type II alveolar epithelial cells protects against lung fibrosis by suppressing TGF-β1 signaling. 2023

Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Type II alveolar epithelial cell (AECII) redox imbalance contributes to the pathogenesis of idiopathic pulmonary fibrosis (IPF), a deadly disease with limited treatment options. Here, we show that expression of membrane-bound cytochrome B5 reductase 3 (CYB5R3), an enzyme critical for maintaining cellular redox homeostasis and soluble guanylate cyclase (sGC) heme iron redox state, is diminished in IPF AECIIs. Deficiency of CYB5R3 in AECIIs led to sustained activation of the pro-fibrotic factor TGF-β1 and increased susceptibility to lung fibrosis. We further show that CYB5R3 is a critical regulator of ERK1/2 phosphorylation and the sGC/cGMP/protein kinase G axis that modulates activation of the TGF-β1 signaling pathway. We demonstrate that sGC agonists (BAY 41-8543 and BAY 54-6544) are effective in reducing the pulmonary fibrotic outcomes of in vivo deficiency of CYB5R3 in AECIIs. Taken together, these results show that CYB5R3 in AECIIs is required to maintain resilience after lung injury and fibrosis and that therapeutic manipulation of the sGC redox state could provide a basis for treating fibrotic conditions in the lung and beyond.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D042966 Cytochrome-B(5) Reductase A FLAVOPROTEIN oxidoreductase that occurs both as a soluble enzyme and a membrane-bound enzyme due to ALTERNATIVE SPLICING of a single mRNA. The soluble form is present mainly in ERYTHROCYTES and is involved in the reduction of METHEMOGLOBIN. The membrane-bound form of the enzyme is found primarily in the ENDOPLASMIC RETICULUM and outer mitochondrial membrane, where it participates in the desaturation of FATTY ACIDS; CHOLESTEROL biosynthesis and drug metabolism. A deficiency in the enzyme can result in METHEMOGLOBINEMIA. Methemoglobin Reductase,NADH Cytochrome B5 Reductase,NADH Methemoglobin Reductase,NADH-Cytochrome B5 Reductase,NADH-Ferrihemoglobin Reductase,B5 Reductase, NADH-Cytochrome,Methemoglobin Reductase, NADH,NADH Ferrihemoglobin Reductase,Reductase, Methemoglobin,Reductase, NADH Methemoglobin,Reductase, NADH-Ferrihemoglobin
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP
D054990 Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change. Cryptogenic Fibrosing Alveolitis,Familial Idiopathic Pulmonary Fibrosis,Fibrocystic Pulmonary Dysplasia,Fibrosing Alveolitis, Cryptogenic,Idiopathic Fibrosing Alveolitis, Chronic Form,Idiopathic Pulmonary Fibrosis, Familial,Interstitial Pneumonitis, Usual,Pulmonary Fibrosis, Idiopathic,Usual Interstitial Pneumonia,Cryptogenic Fibrosing Alveolitides,Dysplasia, Fibrocystic Pulmonary,Fibrocystic Pulmonary Dysplasias,Fibrosing Alveolitides, Cryptogenic,Idiopathic Pulmonary Fibroses,Interstitial Pneumonia, Usual,Pneumonitides, Usual Interstitial,Pneumonitis, Usual Interstitial,Pulmonary Dysplasia, Fibrocystic,Pulmonary Fibroses, Idiopathic,Usual Interstitial Pneumonias,Usual Interstitial Pneumonitides,Usual Interstitial Pneumonitis
D056809 Alveolar Epithelial Cells Epithelial cells that line the PULMONARY ALVEOLI. Pneumocytes,Alveolar Cells,Pneumocyte,Type 1 Pneumocytes,Type 2 Pneumocytes,Type-I Pneumocytes,Type-II Pneumocytes,Alveolar Cell,Alveolar Epithelial Cell,Cell, Alveolar,Cell, Alveolar Epithelial,Cells, Alveolar,Cells, Alveolar Epithelial,Epithelial Cell, Alveolar,Epithelial Cells, Alveolar,Pneumocyte, Type 1,Pneumocyte, Type 2,Pneumocyte, Type-I,Pneumocyte, Type-II,Pneumocytes, Type 1,Pneumocytes, Type 2,Pneumocytes, Type-I,Pneumocytes, Type-II,Type 1 Pneumocyte,Type 2 Pneumocyte,Type I Pneumocytes,Type II Pneumocytes,Type-I Pneumocyte,Type-II Pneumocyte

Related Publications

Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
January 2019, European journal of pharmacology,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
April 2018, Oncology reports,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
May 2022, Molecular medicine reports,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
December 2019, Experimental and therapeutic medicine,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
March 2022, European journal of pharmacology,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
May 2012, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
January 1998, Roczniki Akademii Medycznej w Bialymstoku (1995),
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
November 2020, Molecular medicine reports,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
January 2018, European review for medical and pharmacological sciences,
Marta Bueno, and Jazmin Calyeca, and Timur Khaliullin, and Megan P Miller, and Diana Alvarez, and Lorena Rosas, and Judith Brands, and Christian Baker, and Amro Nasser, and Stephanie Shulkowski, and August Mathien, and Nneoma Uzoukwu, and John Sembrat, and Brenton G Mays, and Kaitlin Fiedler, and Scott A Hahn, and Sonia R Salvatore, and Francisco J Schopfer, and Mauricio Rojas, and Peter Sandner, and Adam C Straub, and Ana L Mora
August 2013, Kidney international,
Copied contents to your clipboard!